Austin, Texas — According to state and local economic development sources Aeglea BioTherapeutics plans to invest $1,513,014.00 to build out 16,560 square feet of new space in Austin. The company plans to occupy the new space at 805 Las Cimas Parkway, Suite 100 in Austin, on or about December 1, 2019. According to the company website Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.

To learn more about Aeglea BioTherapeutics, visit http://www.aegleabio.com/

Company Contact:
Anthony Quinn, Chief Executive Officer
aquinn@aegleabio.com
https://www.linkedin.com/in/anthony-quinn-2566245/
512-942-2935

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved